tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Tirzepatide for Heart Failure with

Sterile water has no preservative and must be used within 24 to 48 hours

Five patients were on dialysis and one had stage 5 chronic kidney disease

Always verify current pricing and terms on official websites before making decisions

Instead, they used the Gila monster discovery as a blueprint for synthetic and semi-synthetic compounds

The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment

The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone